European Cancer Research Association selects the work of our researcher Erick Riquelme as one of the 10 most important works

11-27-2019

Pancreatic cancer is a highly deadly disease, with limited therapeutic options. However, a small group (9%) survives for more than 5 years. The reasons that determine this survival are unknown. In this work, the role of the intratumoral microbiome and its interaction with the immune system in determining this greater survival was determined. It was detected that tumors of patients who have a long survival have greater intratumoral microbial diversity and a greater density of intratumoral immune infiltrate (CD3, CD8 and Granzyme B + T cells). Suggesting that microbial diversity contributes to the anti-tumor immune response, favoring the recruitment and activation of T cells, increasing the life expectancy of patients with these tumors. Additionally, the therapeutic potential of the transfer of fecal material from humans to mice was demonstrated, where it was observed that mice transferred with fecal material from patients who survive for a long time develop a smaller tumor, with a strong anti-tumor immune response, compared to mice receiving faecal material from patients with reduced survival. "Our study represents the first report that explores the influence of the intratumoral microbiome on the behavior of a tumor." Dr. Erick Riquelme expressed.

Source: http://magazine.eacr.org/the-eacrs-top-10-cancer-research-publications-november-2019/10/